Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma
{{output}}
MRG003, a novel EGFR-targeted antibody-drug conjugate (ADC), demonstrates significant efficacy in heavily pretreated patients with recurrent or metastatic nasopharyngeal carcinoma. With an objective response rate of 42% and encouraging overall survival, MRG003... ...
